Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication August 8, 2005
- Accepted for publication September 27, 2005
- Published online April 26, 2006.
Copyright & Usage
© 2006 by Society of Nuclear Medicine
Author Information
- Paul Chen 1 ,
- Judy Wang 1 ,
- Kristin Hope 2 , 3 ,
- Liqing Jin 2 , 3 ,
- John Dick 2–5 ,
- Ross Cameron 6 ,
- Joseph Brandwein 2 ,
- Mark Minden 2 , 5 and
- Raymond M. Reilly 1 , 7 , 8
- 1Division of Nuclear Medicine, University Health Network, Toronto, Ontario, Canada; 2Department of Hematology/Oncology, University Health Network, Toronto, Ontario, Canada; 3Department of Cell and Molecular Biology and Department of Medical Oncology, University Health Network, Toronto, Ontario, Canada; 4Department of Medical Genetics and Microbiology, University of Toronto, Toronto, Ontario, Canada; 5Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; 6Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada; 7Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada; and 8Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, Canada
- For correspondence or reprints contact: Raymond M. Reilly, PhD, Leslie Dan Faculty of Pharmacy, University of Toronto, 19 Russell St., Toronto, Ontario, M5S 2S2, Canada. E-mail: raymond.reilly{at}utoronto.ca
Statistics from Altmetric.com
Cited By...
Article usage
Jump to section
Related Articles
Cited By...
- HOXA/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapy
- Experimental Radionuclide Therapy of HER2-Expressing Xenografts Using Two-Step Targeting Nuclisome Particles
- Auger Electron Radioimmunotherapeutic Agent Specific for the CD123+/CD131- Phenotype of the Leukemia Stem Cell Population
- In Vivo SPECT Quantification of Transplanted Cell Survival After Engraftment Using 111In-Tropolone in Infarcted Canine Myocardium
- Drug-Resistant AML Cells and Primary AML Specimens Are Killed by 111In-Anti-CD33 Monoclonal Antibodies Modified with Nuclear Localizing Peptide Sequences
- Trastuzumab-Resistant Breast Cancer Cells Remain Sensitive to the Auger Electron-Emitting Radiotherapeutic Agent 111In-NLS-Trastuzumab and Are Radiosensitized by Methotrexate
- Epidermal Growth Factor Receptor Inhibition Modulates the Nuclear Localization and Cytotoxicity of the Auger Electron Emitting Radiopharmaceutical 111In-DTPA Human Epidermal Growth Factor
- 111In-Labeled Trastuzumab (Herceptin) Modified with Nuclear Localization Sequences (NLS): An Auger Electron-Emitting Radiotherapeutic Agent for HER2/neu-Amplified Breast Cancer
- Carbon Nanotubes: Potential Benefits and Risks of Nanotechnology in Nuclear Medicine
- [Lys40(Ahx-DTPA-111In)NH2]Exendin-4, a Very Promising Ligand for Glucagon-like Peptide-1 (GLP-1) Receptor Targeting
- Nuclear Localizing Sequences: An Innovative Way to Improve Targeted Radiotherapy